- Home
- UBX vs TPST Comparison
UBX vs TPST Comparison
Compare UBX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- TPST
- Stock Information
- Founded
- UBX 2009
- TPST 2011
- Country
- UBX United States
- TPST United States
- Employees
- UBX N/A
- TPST N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- UBX Health Care
- TPST Health Care
- Exchange
- UBX Nasdaq
- TPST Nasdaq
- Market Cap
- UBX 24.6M
- TPST 27.2M
- IPO Year
- UBX 2018
- TPST N/A
- Fundamental
- Price
- UBX $1.00
- TPST $0.70
- Analyst Decision
- UBX Strong Buy
- TPST Strong Buy
- Analyst Count
- UBX 1
- TPST 4
- Target Price
- UBX $8.00
- TPST $20.00
- AVG Volume (30 Days)
- UBX 82.0K
- TPST 1.4M
- Earning Date
- UBX 11-04-2024
- TPST 11-12-2024
- Dividend Yield
- UBX N/A
- TPST N/A
- EPS Growth
- UBX N/A
- TPST N/A
- EPS
- UBX N/A
- TPST N/A
- Revenue
- UBX N/A
- TPST N/A
- Revenue This Year
- UBX N/A
- TPST N/A
- Revenue Next Year
- UBX $33.62
- TPST N/A
- P/E Ratio
- UBX N/A
- TPST N/A
- Revenue Growth
- UBX N/A
- TPST N/A
- 52 Week Low
- UBX $1.00
- TPST $0.70
- 52 Week High
- UBX $2.02
- TPST $6.00
- Technical
- Relative Strength Index (RSI)
- UBX 28.85
- TPST 24.08
- Support Level
- UBX $1.10
- TPST $0.86
- Resistance Level
- UBX $1.23
- TPST $0.86
- Average True Range (ATR)
- UBX 0.06
- TPST 0.07
- MACD
- UBX -0.01
- TPST -0.01
- Stochastic Oscillator
- UBX 0.00
- TPST 0.00
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.